These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2007-000163-26||A randomised, two-period cross-over, multicentre, double-blind, single-dose, placebo-controlled study to assess the local analgesic effect of CAM2028 in head-and-neck cancer patients suffering from ra...||2007-11-04||due-trials|
|Reported results||2013-000533-12||A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Two Patient Groups with Acromegaly and Neuroendocrine Tumours (NET) ...||2016-02-16||due-trials|
|Reported results||2014-001074-34||A Phase II, Open Label, Active Control, Multi-National, Multi-Centre, Randomized, Parallel Group Study Assessing Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of CAM2032 q1m (Leuprolide Acet...||2015-11-10||due-trials|
|Ongoing||2019-001191-11||A Phase 3, randomized, double-blind, placebo-controlled, multi-center trial to assess efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly||not-yet-due|
|Ongoing||2019-002190-66||A Phase 3, open-label, single-arm, multi-center trial to assess the long term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly||not-yet-due|
|Ongoing||2019-002444-24||An Exploratory Trial Assessing Vascular Digital Perfusion, Pharmacokinetics, Safety and Tolerability Following a Single Dose of CAM2043 (Treprostinil Subcutaneous Depot) in Patients with Raynaud’s Phe...||not-yet-due|